Evolus, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. This annual filing does not provide a clear standalone fourth-quarter income statement or cash-flow value; the financial results below are for the full year.
Business context
Evolus is a commercial-stage aesthetics company whose sole product is Jeuveau, a botulinum toxin type A product approved for temporary improvement of moderate-to-severe glabellar lines. U.S. sales began in May 2019; sales through a Canadian distribution partner began in October. The European Commission approved Jeuveau in September 2019, and management planned a European launch in 2020. Evolus reported more than 3,500 customer accounts ordering by year-end; accounts that participated in its J.E.T. launch program generated more than 80% of U.S. Jeuveau net revenue. J.E.T. program shipments themselves were not recognized as revenue.
Key financial metrics
| Metric | 2019 | 2018 |
|---|---|---|
| Net revenue | $34.9 million | $0 |
| Gross profit / gross margin | $26.9 million / 77.1% | Not applicable |
| Operating expenses | $125.9 million | $46.1 million |
| Loss from operations | $98.9 million | $46.1 million |
| Net loss | $90.0 million | $46.9 million |
| Net loss per share, basic and diluted | $3.19 | $1.92 |
| Cash used in operating activities | $93.4 million | $25.7 million |
2019 revenue comprised $34.2 million of U.S. product revenue and $0.7 million of Canadian service revenue recorded net. The reported gross margin benefited from one-time reduced launch pricing from the manufacturer; the company cautioned that margin could fluctuate as that inventory is used and marketing programs affect selling prices.
At December 31, 2019, Evolus had $109.9 million of cash and cash equivalents, $19.9 million of short-term investments, and $127.8 million of working capital. Total assets were $240.4 million and stockholders’ equity was $79.5 million. Long-term debt was $73.5 million net of discounts and issuance costs, representing $75.0 million of funded principal. Debt carried interest at the greater of 9.5% or 30-day LIBOR plus 7.0%; the effective rate was approximately 11.6%. The additional $25.0 million loan tranche was not available unless sales milestones and other conditions were met; Evolus had not met the sales milestone at year-end.
Changes versus the prior comparable year
- Revenue began with the 2019 commercial launch; there was no revenue in 2018.
- SG&A rose $84.5 million to $113.6 million, primarily reflecting the U.S. launch, sales-force hiring, commercial infrastructure, marketing and J.E.T. program expenses.
- R&D declined $2.5 million to $4.0 million, mainly because U.S. clinical-trial activity was completed in 2018; 2019 included $1.6 million of approval-related bonuses.
- Operating cash use increased by $67.7 million to $93.4 million, reflecting operating losses, working-capital needs, inventory purchases and commercialization spending.
- Net loss widened by $43.2 million. Interest expense increased to $8.0 million, primarily due to Oxford debt and the founders’ contingent promissory note. A $15.0 million income-tax benefit, principally from a partial valuation-allowance release after FDA approval, reduced the reported net loss.
Outlook, risks and unusual items
- Management expected operating losses and negative operating cash flows to continue for at least the next 12 months, while stating that cash, cash equivalents and short-term investments were expected to fund the current operating plan for at least 12 months from the filing date. Additional financing may be needed if adoption or revenue is weaker than expected.
- The company depends entirely on Jeuveau for revenue and on Daewoong as its sole manufacturer. The license includes minimum purchase or market-share requirements for exclusivity and up to $10.5 million of remaining contingent milestone payments at year-end.
- Medytox alleges trade-secret misappropriation involving the manufacturing process and bacterial strain. A related ITC case brought by Medytox and Allergan sought orders that could bar Jeuveau imports and U.S. sales. Evolus disputed the claims and said it could not estimate the likelihood or amount of loss. The ITC’s final determination was targeted for October 6, 2020.
- The Oxford facility is secured by substantially all company assets and includes restrictive covenants and litigation- and license-related default provisions. A default could accelerate repayment and permit remedies against collateral.
- Other notable obligations include a $20.0 million founders’ promissory note maturing in November 2021 and low-single-digit royalties on Jeuveau net sales. The company reported no off-balance-sheet arrangements.
- Jeuveau is an elective, self-pay treatment, making demand sensitive to consumer spending, pricing and competition. The filing highlights established competitors, potential new products, regulatory compliance, product-safety and supply-continuity risks.
Most important facts for investors to verify
- Whether Jeuveau can sustain customer adoption and convert launch-program participation into repeat, paid orders at commercially viable pricing.
- Subsequent revenue, gross margin and cash-burn trends, including the effect of rebates, coupons and the end of one-time launch pricing.
- Whether the company met the sales and covenant requirements for the additional Oxford tranche, and its financing runway relative to its spending needs.
- Developments and potential outcomes in the Medytox litigation and ITC proceedings, including any effect on U.S. imports, sales, licensing rights or debt covenants.
- Daewoong’s manufacturing reliability and Evolus’s ability to maintain contractual exclusivity and meet purchase or market-share requirements.
- The timing and commercial contribution of the planned European launch and other international distribution efforts.